Literature DB >> 26530373

Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer.

Thorsten H Ecke1.   

Abstract

The treatment of metastasized bladder cancer has been evolving during recent years. Cisplatin based chemotherapy combinations are still gold standard in the treatment of advanced and metastasized bladder cancer. But new therapies are approaching. Based to this fact biological markers will become more important for decisions in bladder cancer treatment. A systematic MEDLINE search of the key words "cisplatin", "bladder cancer", "DNA marker", "protein marker", "methylation biomarker", "predictive marker", "prognostic marker" has been made. This review aims to highlight the most relevant clinical and experimental studies investigating markers for metastasized transitional carcinoma of the urothelium treated by cisplatin based regimens.

Entities:  

Keywords:  Adjuvant chemotherapy; Bax; Bcl-2; Biomarker; Bladder cancer; C-reactive protein (CRP); CD40; Chemotherapy; Cisplatin; ERCC1; Emmprin; HER2/neu; Human epidermal growth factor receptor 2 (HER-2); Ki-67; MDR1; Metallothionein (MT); Smac/DIABLO; Survivin; TLX3 gene; Tissue polypeptide antigen (TPA ); Transcription factor TFAP2α; p53

Mesh：

Substances：

Year:  2015        PMID： 26530373     DOI： 10.1007/978-94-017-7215-0_18

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


  5 in total

1.  Enhanced phosphorylation of c-Jun by cisplatin treatment as a potential predictive biomarker for cisplatin response in combination with patient-derived tumor organoids.

Authors:  Yoshiyuki Tsukamoto; Shusaku Kurogi; Tomotaka Shibata; Kosuke Suzuki; Yuka Hirashita; Shoichi Fumoto; Shinji Yano; Kazuyoshi Yanagihara; Chisato Nakada; Fumi Mieno; Keisuke Kinoshita; Takafumi Fuchino; Kazuhiro Mizukami; Yoshitake Ueda; Tsuyoshi Etoh; Tomohisa Uchida; Toshikatsu Hanada; Mutsuhiro Takekawa; Tsutomu Daa; Kuniaki Shirao; Shuichi Hironaka; Kazunari Murakami; Masafumi Inomata; Naoki Hijiya; Masatsugu Moriyama
Journal:  Lab Invest       Date:  2022-08-03       Impact factor: 5.502

2.  Genome-wide association study identifies four SNPs associated with response to platinum-based neoadjuvant chemotherapy for cervical cancer.

Authors:  Xiong Li; Kecheng Huang; Qinghua Zhang; Jin Zhou; Haiying Sun; Fangxu Tang; Hang Zhou; Ting Hu; Shaoshuai Wang; Yao Jia; Ru Yang; Yile Chen; Xiaodong Cheng; Weiguo Lv; Li Wu; Hui Xing; Lin Wang; Shasha Zhou; Yuan Yao; Xiaoli Wang; Quzhen Suolang; Jian Shen; Ling Xi; Junbo Hu; Hui Wang; Gang Chen; Qinglei Gao; Xing Xie; Shixuan Wang; Shuang Li; Ding Ma
Journal:  Sci Rep       Date:  2017-01-25       Impact factor: 4.379

3.  Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours.

Authors:  Sofia Cotton; Rita Azevedo; Cristiana Gaiteiro; Dylan Ferreira; Luís Lima; Andreia Peixoto; Elisabete Fernandes; Manuel Neves; Diogo Neves; Teresina Amaro; Ricardo Cruz; Ana Tavares; Maria Rangel; André M N Silva; Lúcio Lara Santos; José Alexandre Ferreira
Journal:  Mol Oncol       Date:  2017-03-02       Impact factor: 6.603

4.  Molecular Changes of Lung Malignancy in HIV Infection.

Authors:  Jianghua Zheng; Lin Wang; Zenghui Cheng; Zenglin Pei; Zhiyong Zhang; Zehuan Li; Xuan Zhang; Dong Yan; Qianlin Xia; Yanling Feng; Yanzheng Song; Weiping Chen; Xiaoyan Zhang; Jianqing Xu; Jin Wang
Journal:  Sci Rep       Date:  2018-09-03       Impact factor: 4.379

5.  MiR-193a-5p Targets the Coding Region of AP-2α mRNA and Induces Cisplatin Resistance in Bladder Cancers.

Authors:  Ji Zhou; Huaxin Duan; Yu Xie; Yichong Ning; Xing Zhang; Na Hui; Chunqing Wang; Jian Zhang; Jianlin Zhou
Journal:  J Cancer       Date:  2016-08-07       Impact factor: 4.207
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.